Vivimed Labs Limited (NSEI: VIVIMEDLAB)
Health Care · Pharmaceuticals · IN
Rs6.24
+27.09% today · -76.5% 1Y
Vivimed Labs Limited (NSEI: VIVIMEDLAB) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.41M and employs 586 people.
Over the last twelve months the share price has lost 76.5%, trading between 4.75 and 29.40.
Tweenvest scores Vivimed Labs Limited across four factors: quality 37/100, value 42/100, growth 0/100. Its strongest factor is value.
VIVIMEDLAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.41M
- Revenue (TTM)
- $8.14M
- P/E
- —
- EPS
- -21.15
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- Rs29.40
- 52-week low
- Rs4.75
- Avg volume (3M)
- —
- Shares outstanding
- 82.91M
- Employees
- 586
- Next earnings
- —
About Vivimed Labs Limited
Established in 1988 and headquartered in Hyderabad, India, Vivimed Labs Limited, along with its associated entities, is an international manufacturer and supplier of diverse products, including active pharmaceutical ingredients (APIs), finished drug formulations, specialized chemicals, and consumer-branded remedies. Its global presence extends across markets such as India, Mexico, Spain, and Hungary, among others. The company's operations are divided into two core segments: the Pharmaceutical Business and the Specialty Chemicals Business. Within its Pharmaceutical division, Vivimed Labs supplies APIs and crucial intermediates to both generic and ethical pharmaceutical companies. It also develops and markets proprietary branded formulations catering to therapeutic areas like ophthalmology, nutraceuticals, dermatology, and pain relief. Additionally, it provides contract manufacturing services for a variety of dosage forms, including capsules, tablets, syrups, liquids, nasal sprays, and ointments. A notable product is Favulous, manufactured for the treatment of mild to moderate COVID-19 cases. The Specialty Chemicals segment boasts a broad portfolio. This includes Jarocol-branded hair dye intermediates essential for permanent, semi-permanent, and temporary hair coloring systems, alongside oxidation dye couplers, bases, and direct and basic dyes. It also produces Reversacol-branded photochromic dyes and antimicrobial agents utilized in applications ranging from plastic additives to antibacterial handwashes. Furthermore, the company manufactures photographic chemicals, such as black and white developers and antifog additives, for medical and industrial X-ray imaging, consumer photography, and graphic arts litho-plate production. Collectively, Vivimed Labs' offerings find extensive application in the home, personal, and industrial care sectors.
- ISIN
- INE526G01021
- Founded
- 1988
- Listed since
- Aug 17, 2005
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.